Marker Therapeutics, Inc.

MRKR

NASDAQ · Biotechnology

$1.24

At close - Sep 23, 4:00 PM EDT - USD

Market Cap$21M

P/E-1.6x

52W High$2.46

Volume64.8K

VCP Research Verdict2026Q1

Clinical Pipeline Development Drives Persistent Capital Erosion

Marker Therapeutics is currently navigating a high-risk transition as it pivots entirely toward its proprietary MultiTAA cell therapy platform, resulting in a complete loss of commercial revenue as of 2026Q1. The company's financial stability remains heavily d...

GrowthContracting

ProfitabilityNegative

ValuationReview

TechnicalsWeak

Explore valuation models

MARKET ACTION

MRKR price & volume

Price trend, volume and key moving averages

Launch Terminal

Loading chart...

Market performance

Price History →

Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return

MRKR-19.48%

S&P 500 (^GSPC)+12.39%

1-Year Return

MRKR+45.27%

S&P 500 (^GSPC)+15.77%

3-Year Return

MRKR-74.22%

S&P 500 (^GSPC)+81.46%

5-Year Return

MRKR-93.03%

S&P 500 (^GSPC)+73.18%

Growth & profitability

Annual revenue & EPS trend

Revenue

Net income

-$12M-13.3% YoY

Free cash flow

-$12M-10.1% YoY

Operating margin

ROIC (TTM)-20410.9%

Avg ROIC 5Y-

ROE (TTM)-68.8%

Piotroski Score2 / 9

Financial Statements →

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History

EPS Beat Rate10/12 (83%)

Revenue Beat Rate7/12 (100%)

Quarter	EPS (Act vs Est)	Revenue (Act vs Est)
Q3 2026Latest Aug 14, 2026	-$0.09+64.0% vs -$0.25	— vs $682,100
Q2 2026 May 15, 2026	-$0.16+11.1% vs -$0.18	$800,000+2.1% vs $783,900
Q2 2026 Mar 18, 2026	-$0.04+81.0% vs -$0.21	$1M+61.3% vs $682,100
Q4 2025 Nov 13, 2025	-$0.12+66.7% vs -$0.36	$1M+70.5% vs $723,000

Historical baseline: 12 quarters analyzedGAAP / Adjusted

MARKET COVERAGE

Latest News

1 Stories

GlobeNewsWire·2d ago

Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies

HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies for the treatment of hematologic malignancies and solid tumors, today highlighted the expanded infrastructure, technical expertise and manufacturing capabilities supporting its lead program, MT-601 (neldaleucel), following the combination of Cellipont Bioservices and Kincell Bio to form Kincellis Advanced Therapies.

Filtered for Marker Therapeutics, Inc.More Headlines

Compare before deciding

Benchmark MRKR against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Marker Therapeutics, Inc. (MRKR)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
MRKRMarker Therapeutics, Inc.Current	$1.24	$20.67M	-1.57	-100%	—	-68.81%	—
FATEFate Therapeutics, Inc.	$2.43	$283.24M	-2.11	-51.24%	-1941.09%	-65.08%	—
AGENAgenus Inc.	$8.40	$349.8M	-2470.59	10.37%	69.76%	—	—
ADCTADC Therapeutics S.A.	$1.31	$166.62M	-1.17	14.85%	-123.03%	—	—
IMVTImmunovant, Inc.	$34.54	$7.13B	-12.47	—	-7585.86%	-69.59%	—
CABACabaletta Bio, Inc.	$2.22	$361.98M	-1.35	—	—	-128.27%	—

Compare MRKR vs Peers

Marker Therapeutics, Inc. (MRKR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs FATE

Most directly comparable listed peer for MRKR.

Scale Benchmark

vs TMO

Larger-name benchmark to compare MRKR against a more recognizable public peer.

Peer Set

Compare Top 5

vs FATE, AGEN, ADCT, IMVT

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

MRKR SEC Filings & Documents

Marker Therapeutics, Inc. (MRKR) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 4, 2026·SEC

Material company update

Mar 19, 2026·SEC

Material company update

Feb 9, 2026·SEC

10-K Annual Reports

FY 2026

Mar 18, 2026·SEC

FY 2025

Mar 31, 2025·SEC

FY 2024

Mar 26, 2024·SEC

10-Q Quarterly Reports

FY 2026

Aug 14, 2026·SEC

FY 2026

May 15, 2026·SEC

FY 2025

Nov 13, 2025·SEC

Get notified when MRKR posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

MRKR Frequently Asked Questions

Marker Therapeutics, Inc. (MRKR) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Marker Therapeutics, Inc.'s revenue?

Marker Therapeutics, Inc. (MRKR) reported $1.2M in revenue for fiscal year 2025. This represents a 921% increase from $0.1M in 1999.

How fast is Marker Therapeutics, Inc. growing?

Marker Therapeutics, Inc. (MRKR) saw revenue decline by 100.0% over the past year.

Is MRKR profitable?

Marker Therapeutics, Inc. (MRKR) reported a net loss of $8.7M for fiscal year 2025.

Dividend & Returns

What is MRKR's return on equity?

Marker Therapeutics, Inc. (MRKR) has a return on equity (ROE) of -68.8%. Negative ROE indicates the company is unprofitable.

What is Marker Therapeutics, Inc.'s free cash flow?

Marker Therapeutics, Inc. (MRKR) had negative free cash flow of $9.8M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in MRKR back in 1999?

Total return calculator · dividends reinvested · 27+ years of data

See returns →

Quarter

EPS (Act vs Est)

Revenue (Act vs Est)

Q3 2026Latest

Aug 14, 2026

-$0.09+64.0%

vs -$0.25

—

vs $682,100

Q2 2026

May 15, 2026

-$0.16+11.1%

vs -$0.18

$800,000+2.1%

vs $783,900

Q2 2026

Mar 18, 2026

-$0.04+81.0%

vs -$0.21

$1M+61.3%

vs $682,100

Q4 2025

Nov 13, 2025

-$0.12+66.7%

vs -$0.36

$1M+70.5%

vs $723,000

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

MRKRMarker Therapeutics, Inc.Current

$1.24

$20.67M

-1.57

-100%

—

-68.81%

—

FATEFate Therapeutics, Inc.

$2.43

$283.24M

-2.11

-51.24%

-1941.09%

-65.08%

—

AGENAgenus Inc.

$8.40

$349.8M

-2470.59

10.37%

69.76%

—

ADCTADC Therapeutics S.A.

$1.31

$166.62M

-1.17

14.85%

-123.03%

—

IMVTImmunovant, Inc.

$34.54

$7.13B

-12.47

—

-7585.86%

-69.59%

—

CABACabaletta Bio, Inc.

$2.22

$361.98M

-1.35

—

-128.27%

—